




On December 31, 2019 in the city of Wuhan, in the Hubei province of China,1 an outbreak 3 
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected. Following the 4 
initial outbreak, the virus spread to other countries via asynchronous patterns, a pattern typical for 5 
infectious diseases due to the presence of multiple contagion sources. On January 30, 2020, the 6 
WHO changed the status of the outbreak to confirm a Public Health Emergency of International 7 
Concern. On March 11 COVID-19 was reclassified as a pandemic by the WHO, and impacted 8 
over 100 countries over the following number of weeks.2,3 9 
As reported on the 20 March, there were 769 confirmed cases of COVID-19 across 37 10 
countries in Africa, and 15 fatalities4. COVID-19 first appeared in Egypt in the first week of March 11 
2020. As of the evening (20:10) of 21st April, 2020, Egypt was ranked 50th out of 212 areas and 12 
countries in terms of the number of patients infected; 147th out of all areas and countries reporting 13 
infections with regards to the total number of infected individuals reported (with 36 infections per 14 
one million population), 106th with regards to the infection recovery rate (26.6% infection 15 
recovery), and 34th with regards to the number of deaths per total infected (7.5%). Until 21st April, 16 
Egypt was reported to have had a total of 3659 infected, 935 recovered; 1270 negative test results 17 
and 276 deaths [ref: https://www.care.gov.eg/EgyptCare/Index.aspx]. It is challenging for 18 
healthcare authorities to publishing accurate figures, reflecting actual totals, and in real time. The 19 
reasons for this may well be linked to limited testing capacity and difficulties in identifying the 20 
cause of death. a 14-day quarantine period was implemented and other preventative measures such 21 
as a partial curfew; with the Government of Egypt announcing an extension of the nationwide 22 
curfew for two further weeks, until April 23rd 2020.5 The curfew covered the hours between 6:00 23 
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pm and 6:00 am. All commercial enterprises and shops were prevented from working after 6:00 24 
pm except food outlets and pharmacies. From April 24th to May 23rd (during Ramadan) The 25 
Presidency of the Council of Egyptian Ministers relaxed some of these preventative measures such 26 
as reducing the curfew by 3 hours (such that it covered 9:00 pm to 6:00 am) and allowed some 27 
businesses and government services offices to reopen in order to stimulate the economy and 28 
facilitate cultural/social practices during Ramadan. 29 
During the pandemic, medically trained personnel, as the backbone of epidemic prevention 30 
and first-line providers of infection control, endured heavy workloads, high risks of infection and 31 
unprecedented work pressures.6,7 In low- and middle-income countries (LMICs), the role of the 32 
private sector has often been neglected in healthcare by international public health communities 33 
and governments.8 Private community pharmacies provide a significant service in healthcare. 34 
Further, in most LMICs, private pharmacies are broadly established9 and provide the initial point 35 
and preferred channel through which members of the community are able  to obtain medications 36 
and healthcare services for the majority of the population in developing countries,10-12 including 37 
Egypt, as only 23 of 60,000 pharmacies are government owned.13 38 
The important value of private pharmacies was further highlighted during the COVID-19 39 
pandemic crisis. However, pharmacies were unable to fulfil their classic role in healthcare as a 40 
source of medication, as pharmaceutical measures such as a COVID-19 vaccines and antiviral 41 
medicines were not available at time of writing and will not be widely available for a long time. 42 
In the current absence of medical treatment and vaccination, the unfolding COVID-19 pandemic 43 
can only be brought under control by significant, rapid and widespread behavioral changes. Social 44 
and administrative science data could help mitigate the COVID-19 crisis to provide insight into 45 
public perceptions of risk, protective behaviors and preparedness measures, public trust and 46 
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knowledge as well as misinformation.14 The methods of communication and channels of 47 
information used by the populace are changing on a continual basis; it is now of the utmost 48 
importance that social science research incorporates information from social media, as many 49 
authorities, including the WHO, use this to reach out to people. 50 
The aim of the present study was to investigate the preparedness of private community 51 
pharmacies to pandemic COVID-19. This encompasses multiple aspects, in terms of the ability to 52 
provide medicinal products, maintain infection control in the pharmacy, and facilitate patient 53 
education. In addition, the study investigated as the levels knowledge and awareness community 54 
pharmacists had with regard to the pandemic, and the degree to which they had been reporting 55 
COVID-19 cases to the responsible healthcare authority. This cross-sectional survey was 56 
conducted from 8 to 19 April 2020, where The daily report of the Ministry of health and population 57 
in Egypt included a marked increase in the incidence of the infection from 1560 people infected 58 
on 8th April (305 recovered, 103 deaths) to 3144 people infected on 19 April (732 recovered, 239 59 
deaths). Geo-locational data for records of COVID-19 cases may play an important role in the 60 
communication and evaluation of risk during outbreaks, especially when these data are available 61 




Community pharmacies in Egypt were assessed for their preparedness for the COVID-19 66 
pandemic using a cross‐sectional survey administered by in-person interview. Approval to perform 67 
the study was granted by authors’ institution. Participants had the study confidentiality statement 68 
4 
 
verbally explained to them, with a signed copy of the approved confidentiality policy being 69 
provided upon request. 70 
The development of the questionnaire was based on existing literature (specifically that 71 
published by the WHO, and Egyptian,18,19 New South Wales and UK government public health 72 
guidelines as well as The International Pharmaceutical Federation (FIP), The pharmacy Guild of 73 
Australia, The British Columbia Pharmacy Association (BCPhA), Pharmaceutical Services 74 
Negotiating Committee (PSNC), and National Institute for Health and Care Excellence (NICE)) 75 
and exploratory interviews with a purposive sample of seven community pharmacists covering a 76 
range of roles and levels of experience.20 This latter was conducted during the last week of March 77 
2020. The questionnaire included 84 questions divided into three sections. The first section 78 
comprised 12 questions covering pharmacists’ demographics (position, years’ experience, and 79 
gender), the demographics of the customers with suspected COVID-19 symptoms (age and gender) 80 
and the nature and degree of symptoms reported by customers to community pharmacists. The 81 
second section contained 69 polar alternative (yes/no answer) questions covering six domains 82 
related to the COVID-19 pandemic: (1) the ability to provide products, (2) infection control, (3) 83 
practice surrounding patient education, (4) knowledge and awareness, (5) barriers, and (6) 84 
facilitators.  The final section comprised three open-ended questions pertaining to whether 85 
questions should be removed, added or modified, required sentence formatting (composition, 86 
terminology), validity of questionnaire content, and seeking any other comments. The first two 87 
sections comprised questions that were predominantly closed‐ended, although space was provided 88 
for expansion. The final section provided the opportunity at the end of the questionnaire for 89 
respondents to add any further comments on the topic. 90 
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Following development of the questionnaire, a pilot of 92 questions was performed 91 
between the 1st and 6th of April 2020 on a random sample of 42 pharmacies in demographically 92 
similar regions in the North, Centre, South and East of Egypt. As a result of feedback obtained 93 
during the pilot, a number of changes were made to the questionnaire; namely the addition and 94 
removal of certain questions, and modifications to the formatting. 95 
The final questionnaire comprised 87 questions in two sections; a first section containing 96 
12 demographics questions and a second section of 69 questions covering the domains under 97 
investigation. The final section of open-ended questions was removed.  Invitations to take part in 98 
the research were distributed in printed format to community pharmacies in Egypt. Envelopes were 99 
addressed to “the pharmacist” to ensure that respondents were actively working in community 100 
pharmacy, and also to maximize the response rate through obtaining the attention of the 101 
pharmacist. Data collectors then visited community pharmacists in person, to conduct the 102 
interview. One pharmacist was interviewed in each private community pharmacy. All questions 103 
had yes/no answers, except those with multiple closed options, e.g. regions (North, Centre, South, 104 
or East), position (junior, senior, or manager), and years’ experience (list of numbers). Each 105 
questionnaire was assigned a specific data collector (name and ID) to allow the researcher to 106 
contact them if necessary. Data collectors were asked to complete the interviews within a two week 107 
period and submit the answers electronically using Google forms. Following electronic submission 108 
of completed responses, all participant data were anonymized. As such, the survey design had the 109 
advantages of capturing responses from individual personnel covering a large geographical range, 110 
with great rapidity. The present article covers 4 domains out of the 6 covered in the survey, 111 
comprising 45 questions out of the total 69. These 4 domains are: (1) the ability to provide 112 
products, (2) infection control, (3) knowledge and awareness, and (4) practices surrounding patient 113 
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education. The results have been divided into two manuscripts as relevant to the relative directions 114 
of the objectives of the study. The present manuscript deals with the four domains covering 115 
preparedness of community pharmacies for the COVID-19 pandemic (internal consistency 116 
measured by Cronbach's alpha = 0.773). 24 further questions covering the two remaining domains 117 
(barriers and facilitators) relate to a different objective; the development and scaling up of services 118 
provided through community pharmacies (Cronbach's alpha = 0.744). 119 
Data were analysed in SPSS version 20 using descriptive statistics and comparative 120 




1034 questionnaires were sent out to community pharmacists, and 1018 (98.5%) of these 125 
were completed within two weeks, therefore comprising the study sample. One pharmacist was 126 
interviewed in each private community pharmacy. The formal calculations21,22 involved values of 127 
population, confidence level, percentage of response distribution, and confidence interval, taken 128 
to be 70,000, 95%, 50%, and 3.05 respectively. Due to the presence of a small number of missing 129 
values in the data, the results tables presented here show both absolute numbers of respondents 130 
and the percentage of valid responses for transparency. 131 
Respondents covered all three levels of community pharmacist position (junior, senior and 132 
manager) working in community pharmacies of three regions South, East, Centre, and North. 133 
Respondents had a mean age of 36.1, graduated between 1971 and 2019, and ranged in experience 134 
from 1 to 50 years (mean experience = 12.7 years). The majority of respondents had graduated 135 
from Government-funded Universities (82.2%). 21.3% of respondents had received pandemic 136 
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training. .Few respondents (8.8%) had reported a suspected COVID-19 case (Table 1a), and most 137 
(62.9%) of those who had reported cases did not receive pandemic training (Table 6a). With regard 138 
to the customers presenting with suspected symptoms of COVID-19, 42.8% of cases presented 139 
with mild symptoms, (40.5%). The numbers of customers presenting with different symptom 140 
severities, together with the breakdown of customer age and gender are presented in Table 1b. 141 
Availability of hand sanitizers, disinfectants, face masks, antipyretic drugs, thermometers, 142 
cold fomentation, and disposable gloves was better than the availability of alcohol (at least 70% 143 
concentration). A home delivery service was available in about one half of pharmacies, with 144 
significant differences between regions (Centre = 67.1%, North = 41.0%, South = 44.1% and East 145 
= 48.0%; P<0.001). Antimalarial drugs were available only in 39.1% of pharmacies (Table 2). 146 
Most items related to infection control were available at pharmacies; the majority of behaviors 147 
advised to prevent the spread of the virus were adopted by pharmacy staff (up to 99.5%), with the 148 
exception of decreasing the numbers of unnecessary workers to decrease the likelihood of disease 149 
transmission (only adopted in 85.7% of pharmacies). However, instructing staff with chronic 150 
illnesses or any other medical vulnerability to take leave showed a great disparity in the level of 151 
adoption across regions (Centre = 91.5%, North = 97.2%, South = 97.8% and East = 97.3%; 152 
P=0.004). 153 
 In comparison to infection control measures concerning worker-worker interactions, 154 
infection control around worker-customer interactions was given much lower priority. The 155 
availability of card payment machines (29.1% overall) was significantly different between regions 156 
(Centre = 42.1%, North = 24.5%, South = 35.5% and East = 30.7%; P<0.001). As shown in Table 157 
3, pharmacists reported low availability of free hand sanitizers (62.1%) and masks (86.5%) for 158 
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customer use, low adoption of a separate area in the pharmacy for symptomatic customers (64%), 159 
and low implementation of special waste disposal measures (80.4%). 160 
Respondents expressed a high awareness (97.6% - 99.2%) of the hygiene practices 161 
required, the risk of recent travel abroad, the importance of controlling contact with infected cases, 162 
and the common symptoms of COVID-19, but only 91% of pharmacists reported awareness of all 163 
10 possible symptoms (see Table 4). Pharmacists expressed a higher incidence of educating of 164 
costumers verbally (90.4%), compared to providing written information (81.3%). Furthermore, 165 
managers were less likely than juniors and seniors to provide customers with written educational 166 
material (managers = 78.1, juniors = 82% and seniors = 86.8%; P=0.027), and more likely to 167 
communicate this education verbally (managers = 98.3%, juniors = 91.8% and seniors = 90%; 168 
Table 5). Only 8.8% of pharmacists had reported cases with suspected COVID-19 symptoms to 169 




Controlling the spread of COVID-19, and thus bringing the pandemic to an end, can only 174 
be achieved by widespread and rapid implementation of significant changes to human behavior. 175 
At time of writing, there is no vaccination available and insufficient supplies of the medicines use 176 
to treat the disease. Observations of a social science nature could provide insight into behaviors 177 
and perceptions among the populace, as well  preparedness measures employed by authorities and 178 
the level of public trust in them.14 The WHO reports the use of real-time geo-positioned data or 179 
information in order to effectively communicate and evaluate statistics during outbreaks.15-17 This 180 
data can then be used to reach out to healthcare professionals and the general population. In 181 
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contrast to and the majority of businesses, community pharmacies are able to supply customers in 182 
their local communities with medicines, hygiene products and essential information throughout 183 
the pandemic.23,24 Public panic, together with significant increases in demand for products, 184 
increases the pressure on already busy pharmacy staff. 25,26 This article reports the preparedness of 185 
community pharmacists across Egypt for the COVID-19 pandemic. 186 
 187 
Availability and distribution of products and medicines 188 
 189 
Critical supply shortages of Personal Protective Equipment (PPE) and hygiene products 190 
during the COVID-19 Pandemic are international problem. Lack of adequate PPE for frontline 191 
healthcare workers, together with estimates that countries will need far more face masks and 192 
respirators than are currently available27 highlight problems with the global supply chain. As at 193 
January 2020, half the world’s face masks were produced in China28, but exports decreased as the 194 
infection spread and China’s usage increased. Following the peak of the pandemic passing in 195 
China, the export of face masks increased again.28 196 
In surveyed pharmacies, necessary products such as hygiene products, antipyretic drugs, 197 
cold fomentations or ice packs and PPE (Table 2) were not available at all pharmacies, especially 198 
high concentration alcohol. Although community pharmacies strive to continue functioning as a 199 
business, it becomes necessary to prioritize maintaining adequate stock of the essential items 200 
according to local customer demand. Further, modification of package sizing and imposing 201 
customer limits on purchase quantities may be necessary, for example dividing large packets of 202 
Paracetamol into smaller ones and limiting the number sold to each customer to meet 203 
unprecedented demand.29,30 204 
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Recent researches suggest Chloroquine and its derivatives to be effective in the treatment 205 
of COVID-19 patients.31-36 The present study found such quinine-based antimalarial drugs only to 206 
be available in 39.1% of pharmacies, a direct result of panic buying in response to the pandemic. 207 
This resulted in a shortage of the drugs for the treatment of other immunological conditions such 208 
as rheumatoid arthritis and lupus. 209 
Approximately half the pharmacies surveyed reported to offer home delivery services. The 210 
need for such delivery services will vary across a region, dependent on the population it serves. 211 
Delivery drivers will also need access to the same resources afforded to pharmacy staff, such as 212 
PPE, hygiene products and education on behavioral measures to prevent the spread of COVID-19. 213 
Moreover, it may be necessary to place a limit on the quantities of certain items that can be ordered 214 
by each household. Other additional remote services should be considered to reduce contact 215 
between individuals, such as telephoning patients to let them know when their prescription is ready 216 
to be collected, as opposed to patients making multiple unnecessary visits to the pharmacy to check 217 
on the progress of a prescription.  218 
Governments and policy makers are advised to do everything in their power to ensure 219 
availability of medicines and hygiene products. To address the PPE shortage in Egypt, the National 220 
Service Projects Organization, a department of the Egyptian Armed Forces intervened to provide 221 
alcohol, disposable gloves, sanitizers, disinfectants and face masks directly to the public from one 222 
of its owned companies (ElNast Intermediate Chemicals Co.). In the UK, the government 223 
announced plans to assist with the funding of a pharmacy delivery service to facilitate timely 224 
access to medicines for the most vulnerable patients.37 225 
 226 




In Italy, inadequate access to PPE contributed to high rates of infection and death for 229 
healthcare workers.38 It is imperative that all healthcare workers including community pharmacists 230 
have access to adequate supplies and equipment.  231 
 232 
- Inside the pharmacy 233 
 234 
For the majority, maintenance of a clinical environment in the pharmacy, and hygienic 235 
interactions of pharmacy staff were suitably prioritized. This included increasing the frequency of 236 
regular cleaning of clinical areas, and paying extra attention to areas known to be implicated in 237 
spreading disease (counter tops, door handles, pens, etc.). Planning is required in the 238 
implementation of these measures for the protection of patients/customers and staff.39 By way of 239 
an example, the National Health Service in England advised community pharmacy staff to order 240 
small quantities of gloves, aprons and fluid-repellent face masks for use by staff and not to be sold 241 
to the public.40 242 
Unfortunately, the disposal of used PPE and other waste management was only considered 243 
in 80.4% of the pharmacies surveyed. Adequate provision of waste bins is a necessity. Any waste 244 
likely to carry COVID-19 must be double-bagged and/or separated from general waste for 72 hours 245 
disposal41 to decrease the risk of transmission outside the pharmacy.  246 
While some individuals do not meet the requirements for shielding, they may still be at 247 
higher risk if they contract COVID-19. If these individuals are members of pharmacy teams, plans 248 
must be made to ensure their safety while working. 85.7% of the pharmacies surveyed decreased 249 
the number of unnecessary workers onsite to decrease the likelihood of disease transmission. 250 
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Vulnerable staff were allowed leave in 95.7% of pharmacies, and those chronic disease were 251 
allowed leave in 96.4% of cases, again to prevent infecting staff members who are at higher risk. 252 
However, this was not the case in all regions, with the Central region having the lowest incidence 253 
of implementing this policy, perhaps containing the capital city (Cairo) and economic center places 254 
additional pressures on the workers. Stringent physical distancing behavior is strongly advises for 255 
high-risk individuals,39 i.e. those aged 70 years or over, and those with underlying health 256 
conditions, such as heart disease or diabetes. 257 
 258 
- Interpersonal interactions 259 
 260 
There is evidence of pre-symptomatic transmission from studies in Singapore and other 261 
countries,42,43 suggesting that viral shedding occurs prior to symptom onset. Not all pharmacy 262 
workers report the use of PPE.40 In the present study, pharmacists reported paying less attention to 263 
infection control when interacting with customers, compared to when interacting with other staff. 264 
Despite precautions taken to protect pharmacy staff, it is inevitable that they will interact with 265 
patients when dealing with crowds of customers, dispensing prescriptions and taking payments.  266 
Due to the role of respiratory droplets in the transmission of COVID-19, transmission is 267 
accelerated by high population densities, such as those in pharmacies and other healthcare and 268 
commercial sectors. Customer crowding is important, as customers are dynamic (different people) 269 
rather than static like pharmacy staff. Avoiding customer crowding and instructing customers to 270 
keep at least one meter distance were measures used by the community pharmacists surveyed. 271 
Community mitigation strategies, including cancelling mass gatherings, are recommended to 272 
reduce disease transmission,44 resulting in substantial reductions in the numbers of people infected, 273 
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and ultimately, deaths.45 The success of these strategies relies on timely implementation, 274 
specifically before high levels the virus become present in the community.46,47 275 
In developing countries (including Egypt), prescriptions in community pharmacies are still 276 
printed and collected in person rather than using electronic prescription services (EPS) such that 277 
are commonplace in developed countries (including the UK). Efficient planning is required to 278 
ensure that prescriptions are collected while minimizing contact,48 including provision for general 279 
practitioners to send paper prescriptions directly to pharmacies.49 280 
Interactions around payments can also be implemented, including the widespread use of 281 
contactless payment where possible. Unfortunately, card payment machines were only available 282 
29.1% of the pharmacies surveyed. Use of these machines would help reduce the role of cash as a 283 
source of disease transmission, and further reduce physical contact. Availability of card payment 284 
was also significantly different across regions, with the Central region again as the country’s 285 
capital having a more developed infrastructure and wider availability of card payment. 286 
Pharmacy staff working in any national crisis endure risks in fulfilling their role and all 287 
possible measures must be taken to ensure their continued safety. Free sanitizers (62.1%), and 288 
masks (86.5%) were provided for customer use in surveyed pharmacies, to provide some 289 
protection from transmission. A high degree of anxiety will be experienced by staff about their 290 
patient-facing role and it is important to address these concerns and to advise pharmacy staff to 291 
adopt risk-minimizing behaviors. It is also important to mitigate staff exhaustion where possible. 292 
Another measure often employed is to define a specific area within the pharmacy for 293 
customers with suspected COVID-19 symptoms so as to reduce infection transmission. This 294 
practice was implemented by 64% of pharmacies surveyed, however not all pharmacies have such 295 
a space available inside the pharmacy, with some pharmacies having a total area as small as 25 m2 296 
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(29.89 sq yd) according to Egyptian regulations. In such a small pharmacy, staff may need to 297 
reconsider the use of space. It may be necessary to rearrange the working area to allow more space 298 
between employees, for example to expand a small dispensary area into part of the pharmacy store. 299 
This further may reduce the total number of customers who can enter the store at once, resulting 300 
in queues out of the door. Although not ideal, these temporary measures may be crucial in 301 
protecting pharmacy staff and customers.  302 
However, it is appreciated that such physical distancing measures are not practical in all 303 
pharmacies, the next line of defense is to use PPE. Public Health England (PHE) regularly updates 304 
guidance on PPE use for healthcare professionals. Most recently (as at 10th April 2020) the 305 
recommendation was that for pharmacy staff, fluid-resistant masks should only be worn when in 306 
“contact with possible or confirmed cases of COVID-19”50. 307 
 308 
Customer education 309 
 310 
Due to measures in place during the pandemic, a pharmacy may need to decrease their 311 
focus on retail and increase the focus on education and the dispensing of information. Pharmacists 312 
surveyed reported educating costumers in behaviors such as avoiding touching the face, avoiding 313 
sneezing or coughing near people, sneezing or coughing into the elbow, avoiding unnecessary 314 
travel, staying at home and communicating where possible by telephone, and accessing healthcare 315 
services in the event of a suspected infection. 316 
Pharmacists preferentially used oral communication (90.4%), rather than written (81.3%) 317 
in educating costumers. Further, managers, were less likely to use written communications than 318 
more junior grades of staff, and more likely to use oral communications. In the contrary, the 319 
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opposite is recommended; written communication may be more adequate in the current pandemic 320 
situation; decreasing the time a customer spends in the pharmacy, and as such  decreasing 321 
overcrowding and decreasing contact time between customers and pharmacists. Therefore, such 322 
communication can be assisted and reinforced using posters, banners or signs on display in a 323 
prominent position, for example on the door as they enter, to inform patients about services the 324 
pharmacy can provide at this time as well as educating them as to best practice behaviors. This 325 
will also assist in limiting the number of people entering the store at one time and ensuring people 326 
only shop when it is essential to do so. Attention can be drawn specifically to these information 327 
posters by temporarily removing any other posters that may distract customers from information 328 
related to COVID-19. Further, any information presented must be reviewed daily to ensure that it 329 
is current and correct.51 330 
Early figures from the U.S. reported 80% of deaths to be in people over the age of 65, with 331 
the risk significantly increasing in individuals from around 80 years of age with underlying 332 
conditions.52 Pharmacists surveyed showed high consideration for the education of vulnerable 333 
people, for example geriatrics and patients with chronic diseases. This is necessary to reduce 334 
suffering at the end of life, and help people with serious or life-limiting illness to maintain 335 
autonomy and dignity.53 To neglect to pay close attention when educating these groups results in 336 
costly, ineffective and inefficient care.  337 
 338 
Awareness and reporting  339 
 340 
It is difficult for healthcare practitioners to keep up to date with constantly changing 341 
guidance, but lessons from previous pandemics are available. Authority in epidemic response must 342 
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be evidence based. Similar to a community pharmacist’s preparedness to perform their important 343 
role in the spontaneous reporting of adverse drug reactions, the reporting of suspected COVID-19 344 
cases is equally crucial. 345 
Pharmacists reported high clinical knowledge and awareness of practicing good hygiene, 346 
the risk of recent travel abroad, and both common and uncommon symptoms that differentiate a 347 
COVID-19 infection. Similarly, pharmacists understood the importance of controlling contact with 348 
infected patients, but only 8.8% had the courage to report symptomatic cases to the healthcare 349 
authority. However, partial reporting of cases suspected cases in such conditions is better than not 350 
reporting at all, as it contributes to simultaneous surveillance studies, epidemiological field 351 
investigations and case series54 in helping to develop national reports about disease incidence.  352 
Significant differences in the demographics of pharmacists were found between non-353 
reporters and reporters; namely geographic region (p<0.001), whether or not COVID-19 training 354 
had been completed (p<0.001; surprisingly, most of those to have reported cases had not been 355 
trained for the COVID-19 pandemic), their position (p=0.019), and age (p=0.046; Table 6a). These 356 
are in line with similar findings of the CDC COVID-19 Response Team published in their 357 
Morbidity and Mortality Weekly Report entitled “Geographic Differences in COVID-19 Cases, 358 
Deaths, and Incidence — United States”. The number of reported cases was seen as likely to be an 359 
underestimate due to incomplete detection of cases and delays in case reporting. A geographical 360 
variation in reporting completeness was attributed to differing testing and reporting practices 361 
across jurisdictions, and differing capacities across jurisdictions to cope with the sudden high 362 
demand on health department infrastructure. Further, transmission rates, incidence and death rates 363 
may genuinely differ on a regional basis. There may be “hot spots” and also areas of extremely 364 
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low transmission due to highly efficacious community mitigation efforts which are not reflected 365 
in this scale of analysis.55  366 
The preparedness of community pharmacists for a pandemic outbreak such as COVID-19 367 
is not limited to the classic role in the pharmacy, but should also be considered to cover the role 368 
of adequately reporting suspected COVID-19 cases to healthcare authorities, hence monitoring 369 
disease spread and contributing to the reliability and validity of national figures. A parallel should 370 
be drawn with the pharmacist’s role of reporting adverse drug reactions, especially at the current 371 
time of pandemic. As such, it is beneficial to avoid underreporting or over reporting that affect the 372 
accuracy of reports. It is also beneficial to keep up to date with reliable information sources about 373 
pandemic progress and with published guidelines.56,57 Efficient and effective routine reporting of 374 





In the current absence of medical treatment, social science data provides an invaluable 380 
addition to clinical data in mitigating the crisis. With a significant increase in demand for the 381 
supply of information and medicines, community pharmacies will continue to serve local 382 
communities, unlike many other services and businesses.  As a result, community pharmacies 383 
preparedness for this role is crucial. There are global shortages of PPE and medicines. As a result, 384 
governments and policymakers are doing all they can to address this shortage. Community 385 
pharmacists are exposed to high infection risks, and are especially vulnerable due to frequent 386 
contact with patients. Accordingly, infection control measures should be considered during all staff 387 
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interactions with each other (maintaining workplace hygiene and waste management) and with 388 
customers (maintaining physical distance, taking care handling prescriptions, use of contactless 389 
payment methods, and providing suspected COVID-19 patients with their own definite area and 390 
free masks and hand sanitizers). It is paramount to ensure the health and safety of frontline 391 
pharmacists amongst other healthcare professionals to ensure continuity and functionally of their 392 
roles in the community. Educating customers, especially those at high risk, is essential during a 393 
pandemic. Posters, banners or signs must include regularly updated information so as to decrease 394 
patient contact and reduce crowding in-store. Pharmacists’ own awareness and up-to-date 395 
knowledge are also essential. Accordingly, pandemic preparedness of pharmacists must not be 396 
overlooked, and should be extended to knowledge of accurate reporting procedures. Avoidance of 397 
under-reporting and over-reporting is important in order that pharmacists’ reports of suspected 398 
infected cases contribute constructively to national reports of the spread of infection. 399 
 400 
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